You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Submits Comments Re: Methods for Assuring Access to Covered Medicaid Services Final Rule with Comment

<div>
Andrew Slavitt</div>
<div>
Acting Administrator</div>
<div>
Centers for Medicare &amp; Medicaid Services</div>
<div>
Department of Health and Human Services</div>
<div>
Hubert H. Humphrey Building, Room 445-G</div>
<div>
200 Independence Avenue, SW</div>
<div>
Washington, DC 20201</div>
<div>
&nbsp;</div>
<div>
Re: Medicaid Program; Methods for Assuring Access to Covered Medicaid</div>
<div>
Services; Final Rule with Comment [CMS-2328-FC]</div>
<div>
&nbsp;</div>
<div>
Dear Acting Administrator Slavitt:</div>
<div>
&nbsp;</div>
<div>
The Biotechnology Industry Organization (BIO) is pleased to submit comments on</div>
<div>
the Centers for Medicare and Medicaid Services&rsquo; (CMS&rsquo;s) final rule with comment entitled</div>
<div>
Medicaid Program; Methods for Ensuring Access to Covered Medicaid Services; Final Rule with Comment (the &quot;FC&quot;).&nbsp;</div>

Andrew Slavitt
Acting Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building, Room 445-G
200 Independence Avenue, SW
Washington, DC 20201
 
Re: Medicaid Program; Methods for Assuring Access to Covered Medicaid
Services; Final Rule with Comment [CMS-2328-FC]
 
Dear Acting Administrator Slavitt:
 
The Biotechnology Industry Organization (BIO) is pleased to submit comments on
the Centers for Medicare and Medicaid Services’ (CMS’s) final rule with comment entitled
Medicaid Program; Methods for Ensuring Access to Covered Medicaid Services; Final Rule
with Comment1 (the “FC”).
 
BIO is the world's largest trade association representing biotechnology companies,
academic institutions, state biotechnology centers and related organizations across the
United States and in more than 30 other nations. BIO’s members develop medical products
and technologies to treat patients afflicted with serious diseases, to delay the onset of
these diseases, or to prevent them in the first place. In that way, our members’ novel
therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also
have reduced healthcare expenditures due to fewer physician office visits, hospitalizations,
and surgical interventions.

See the full comment letter here.